|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.05/-2.03
|
企業價值
44.70M
|
資產負債 |
每股賬面淨值
0.77
|
現金流量 |
現金流量率
--
|
損益表 |
收益
15.53M
|
每股收益
0.21
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
![](../images/dot.bmp)
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. |